Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Overview Trevena Inc. (Nasdaq: TRVN) is set to present tomorrow February 12 at 9:15 EST at the 21st Annual BIO CEO & … [Read more...] about TRVN to Present at BIO & CEO Conference
Introduction Recro Pharma (NASDAQ: REPH) engages in the research and development of non-opioid therapeutics for the treatment of acute postoperative pain. REPH is currently developing three … [Read more...] about $REPH – Recro Pharma, PDUFA Swing Trade
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Good Morning! We hope you all are enjoying your early morning trading! Today, three companies we … [Read more...] about Morning Update-Form 13G’s On Deck!
Introduction Trevena Inc. (Nasdaq: TRVN) spiked 119% from the $.5 range to $1.19 on January 28th. The catalyst being positive regulatory updates from the FDA Type A meeting minutes. In a nut-shell the … [Read more...] about 2019 Should Be A Good Year For TRVN, But What’s Next?
Question by deadpool from StockTwits: Q: "how do you feel about ACRX price action today seems like just a red market is tearing everything down. i am hopeful we get back up to 3.30s next week" Thanks … [Read more...] about A Question about ACRX price decline after Dsuvia approval
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
MS Money Moves Swing thesis for AcelRX Pharma (ACRX) published last week in our "Swing Alert"article played out nicely. ACRX spiked ~70% from $2.90 to $4.92 in the last 5 trading sessions. The upward … [Read more...] about ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It
GALT’s phase 3 study inclusion criteria will be patients diagnosed with NASH-cirrhosis but without varices, and includes an interim analysis. Competition in the NASH-cirrhosis space is lacking. The … [Read more...] about Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval and Potential Buyout
Overview Swing Trading is a trading strategy that involves buying a stock at lower price and selling it at a higher price over a short period of time. Return on investment targets range from … [Read more...] about Swing Trading a Biotech Stock